AGIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Agios Pharmaceuticals Inc (AGIO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has recently received FDA approval for Aqvesme, which is expected to drive long-term growth. Positive analyst sentiment, hedge fund buying, and strong financial growth trends further support the investment case.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 62.744, and the stock is trading above key pivot levels. However, moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting caution in the short term. Key resistance levels are at $28.57 and $29.253.
FDA approval of Aqvesme for anemia treatment in thalassemia, with a high WAC price of $425k annually.
Hedge funds are significantly increasing their positions in AGIO, with a 297.63% increase in buying activity last quarter.
Analysts have raised price targets, with several firms maintaining Buy ratings and targets as high as $
Strong YoY financial growth in Q4 2025, with revenue up 86.09% and gross margin at 90.59%.
The company's EPS remains negative at -1.85, though it has improved YoY.
The REMS requirement for Aqvesme may slow initial adoption.
Bearish moving averages indicate potential short-term resistance.
In Q4 2025, revenue increased by 86.09% YoY to $19.97 million. Net income improved by 11.93% YoY to -$108.04 million, and EPS improved by 9.47% YoY to -$1.85. Gross margin increased to 90.59%, reflecting strong operational efficiency. The company also reported a robust cash position of $1.2 billion.
Analysts are optimistic about AGIO, with multiple firms raising price targets following FDA approval of Aqvesme. Price targets range from $25 to $62, with most firms maintaining Buy ratings. Analysts expect gradual adoption of Aqvesme, with acceleration as patient starts normalize.
